Athira Pharma Inc.
0.53
-0.00 (-0.21%)
At close: Jan 14, 2025, 3:59 PM
0.53
-0.09%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 0.52
Market Cap 20.59M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.84
PE Ratio (ttm) -0.19
Forward PE n/a
Analyst Hold
Ask 0.6
Volume 95,978
Avg. Volume (20D) 4,885,731
Open 0.53
Previous Close 0.53
Day's Range 0.52 - 0.57
52-Week Range 0.41 - 4.30
Beta undefined

About ATHA

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkins...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 18, 2020
Employees 65
Stock Exchange NASDAQ
Ticker Symbol ATHA

Analyst Forecast

According to 4 analyst ratings, the average rating for ATHA stock is "Hold." The 12-month stock price forecast is $11.25, which is an increase of 2012.68% from the latest price.

Buy 25.00%
Hold 75.00%
Sell 0.00%
Stock Forecasts
2 months ago · Source
-12.01%
Althira Pharma shares are trading lower after the ... Unlock content with Pro Subscription
2 months ago · Source
+15.73%
Athira Pharma shares are trading higher after the company announced it will present results from its Phase 2/3 LIFT-AD clinical trial of Fosgonimeton to treat Alzheimer's disease.